LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Meta Expands AI Training With Employee Activity Tracking Tools 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
EDEN PRAIRIE, Minn., March 07, 2016 -- Sunshine Heart, Inc. (Nasdaq:SSH) announced today that its Chief Executive Officer and President, John Erb, is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston, MA on March 8th at 10:40 AM ET.
To access the live webcast, please visit the Investors page of the Sunshine Heart website at http://ir.sunshineheart.com/events.cfm. An audio archive of the webcast will be available following the call on the Company’s website.
About the C-Pulse® Heart Assist System
The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System may be able to stop using the device due to sustained improvement in their conditions as a result of the therapy.
Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.
About Sunshine® Heart
Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical study of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal study. In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking statements that are based on management's beliefs, assumptions, expectations, and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without limitation, our expectations with respect to future clinical study activities and results including patient enrollment in studies. These forward-looking statements are subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical studies do not meet their enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and commercialization of our products, that we may not be able to commercialize our products successfully in the EU and the other risk factors described under the caption “Risk Factors” and elsewhere in our filings with the U.S. Securities and Exchange Commission. You should not place undue reliance on forward-looking statements because they speak only as of the date when made and may turn out to be inaccurate. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.
For further information, please contact: Claudia Drayton Chief Financial Officer Sunshine Heart, Inc. T: +1-952-345-4205 Investor Relations [email protected]
